Conference - Philadelphia, PA, United States of America
Since the FDA recently signed the Safety and Innovation Act, which will expedite pediatric drug approval, more pharmaceutical companies are taking pediatric pharmacology and drug development into more consideration. Pharmaceutical companies are maximizing their pre-clinical results from pharmacology studies and are able to more effectively create new treatment methods through pharmacokinetics, pharmacodynamics, and PBPK modeling. There has also been a push to encourage international collaboration with other pharmaceutical companies to engage in pediatric disease research and exchange information globally
The marcus evans 3rd Pediatric Pharmacology Conference will provide delegates with a comprehensive view of the pediatric pharmacology industry, focusing on the effects that conducting pre-clinical and clinical research have on creating a PK profile. By having this unique profile, the ability of modeling adult data to children will be more easily attained and can be utilized in pediatric drug development and formulation.
(Courtesy of Philadelphia. From Wikipedia)
Website: http://www.marcusevansch.com/PEDPharma2013_ELS
Hyatt at the Bellevue - Philadelphia, PA, United States of America
Wed, Jan 23, 2013 - Fri, Jan 25, 2013
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.